
Katarzyna B Winsz-Szczotka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8892112/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Effects of TNF-α Inhibition on the Metabolism of Cartilage: Relationship between KS, HA, HAPLN1 and ADAMTS4, ADAMTS5, TOS and TGF-β1 Plasma Concentrations in Patients with Juvenile Idiopathic Arthritis. Journal of Clinical Medicine, 2022, 11, 2013.	1.0	4
2	Alterations of Extracellular Matrix Components in the Course of Juvenile Idiopathic Arthritis. Metabolites, 2021, 11, 132.	1.3	13
3	Concerted Actions by PIICP, CTXII, and TNF- $\hat{l}\pm$ in Patients with Juvenile Idiopathic Arthritis. Biomolecules, 2021, 11, 648.	1.8	2
4	Association of Circulating COMP and YKL-40 as Markers of Metabolic Changes of Cartilage with Adipocytokines in Juvenile Idiopathic Arthritis. Metabolites, 2020, 10, 61.	1.3	4
5	Plasma Glycosaminoglycan Profiles in Systemic Sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-Beta. BioMed Research International, 2020, 2020, 1-8.	0.9	7
6	Significant Remodeling Affects the Circulating Glycosaminoglycan Profile in Adult Patients with both Severe and Mild Forms of Acute Pancreatitis. Journal of Clinical Medicine, 2020, 9, 1308.	1.0	4
7	Urinary sulphated glycosaminoglycans excretion in obese patients with type 2 diabetes mellitus treated with metformin. Archives of Physiology and Biochemistry, 2019, , 1-7.	1.0	5
8	High-level of circulating progranulin and its relationship with plasma glycosaminoglycans, as biochemical indicators of proteolytic and oxidative aggrecan modification, in the course of juvenile idiopathic arthritis. Postepy Higieny I Medycyny Doswiadczalnej, 2018, 72, 906-912.	0.1	0
9	Adiponectin, Leptin, and Leptin Receptor in Obese Patients with Type 2 Diabetes Treated with Insulin Detemir. Molecules, 2017, 22, 1274.	1.7	16
10	Relationship between adiponectin, leptin, <scp>IGF</scp> â€1 and total lipid peroxides plasma concentrations in patients with systemic sclerosis: possible role in disease development. International Journal of Rheumatic Diseases, 2016, 19, 706-714.	0.9	18
11	Laboratory Indicators of Aggrecan Turnover in Juvenile Idiopathic Arthritis. Disease Markers, 2016, 2016, 1-7.	0.6	7
12	Metabolism of glycosaminoglycans in the course of juvenile idiopathic arthritis. Postepy Higieny I Medycyny Doswiadczalnej, 2016, 70, 135-142.	0.1	11
13	Circulating keratan sulfate as a marker of metabolic changes of cartilage proteoglycan in juvenile idiopathic arthritis; influence of growth factors as well as proteolytic and prooxidative agents on aggrecan alterations. Clinical Chemistry and Laboratory Medicine, 2015, 53, 291-7.	1.4	13
14	Plasma and urinary glycosaminoglycans in the course of juvenile idiopathic arthritis. Biochemical and Biophysical Research Communications, 2015, 458, 639-643.	1.0	10
15	Antioxidant activity and structural modifications of serum chondroitin sulfate in Graves' disease. Clinical Biochemistry, 2014, 47, 19-24.	0.8	7
16	Urinary glycosaminoglycan (uGAG) excretion in healthy pediatric and adolescent population. Clinical Biochemistry, 2014, 47, 1341-1343.	0.8	16
17	Influence of proteolytic–antiproteolytic enzymes and prooxidative–antioxidative factors on proteoglycan alterations in children with juvenile idiopathic arthritis. Clinical Biochemistry, 2014, 47, 829-834.	0.8	13
18	Propolis Induces Chondroitin/Dermatan Sulphate and Hyaluronic Acid Accumulation in the Skin of Burned Wound. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-8.	0.5	38

#	Article	IF	CITATIONS
19	Propolis modulates vitronectin, laminin, and heparan sulfate/heparin expression during experimental burn healing. Journal of Zhejiang University: Science B, 2012, 13, 932-941.	1.3	27
20	Age- and gender-related alteration in plasma advanced oxidation protein products (AOPP) and glycosaminoglycan (GAG) concentrations in physiological ageing. Clinical Chemistry and Laboratory Medicine, 2012, 50, 557-63.	1.4	17
21	Plasma biomarkers of oxidative and AGE-mediated damage of proteins and glycosaminoglycans during healthy ageing: A possible association with ECM metabolism. Mechanisms of Ageing and Development, 2012, 133, 538-548.	2.2	22
22	Age- and gender-dependent changes in circulating concentrations of tumor necrosis factor-α, soluble tumor necrosis factor receptor-1 and sulfated glycosaminoglycan in healthy people. Clinical Chemistry and Laboratory Medicine, 2011, 49, 121-127.	1.4	7
23	Age- and Gender-Dependent Changes in Connective Tissue Remodeling: Physiological Differences in Circulating MMP-3, MMP-10, TIMP-1 and TIMP-2 Level. Gerontology, 2011, 57, 44-52.	1.4	41
24	Age-related changes of plasma glycosaminoglycans. Clinical Chemistry and Laboratory Medicine, 2008, 46, 219-24.	1.4	18
25	Alterations in serum glycosaminoglycan profiles in Graves' patients. Clinical Chemistry and Laboratory Medicine, 2006, 44, 582-8.	1.4	8
26	Alterations of glycosaminoglycan metabolism in the development of diabetic complications in relation to metabolic control. Clinical Chemistry and Laboratory Medicine, 2005, 43, 924-9.	1.4	17
27	Effects of metabolic control and vascular complications on indices of oxidative stress in type 2 diabetic patients. Diabetes Research and Clinical Practice, 2005, 68, 207-216.	1.1	41
28	Graves' disease—associated changes in the serum lysosomal glycosidases activity and the glycosaminoglycan content. Clinica Chimica Acta, 2003, 331, 97-102.	0.5	6
29	Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease during therapy. Clinica Chimica Acta, 2000, 300, 107-117.	0.5	115